염증과 패혈증
Inflammation and Sepsis
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Despite the development of modern intensive care and new antimicrobial agents, the mortality of the patients with severe sepsis and septic shock remains high. The poor outcome is considered to be a consequence of an overactive systemic inflammatory response. Sepsis is now defined as systemic inflammatory response syndrome (SIRS) in which there is an identifiable focus of infection. As a consequence of the overactive SIRS response, the function of various organ systems may be compromised, resulting in multiple organ dysfunction syndrome (MODS) and death. Systemic inflammation is a consequence of activation of the innate immune system. It is characterized by intravascular release of pro-inflammatory cytokines and other vasoactive mediators, and the concurrent activation of the innate immune cells. In addition to the pro-inflammatory reactions, the host`s anti-inflammatory mechanisms are also activated and aimed at counteracting the inflammatory response. The balance between pro- and anti-inflammatory reactions is critical for the outcome of the patient. Understanding the mechanisms of acute inflammatory responses in critical ill patients is necessary for the development of urgently needed therapeutics. The aim of this review is to provide a description of the key components and mechanisms involved in the inflammatory response in patients with SIRS and sepsis.
Abstract
Despite the development of modern intensive care and new antimicrobial agents, the mortality of the patients with severe sepsis and septic shock remains high. The poor outcome is considered to be a consequence of an overactive systemic inflammatory response. Sepsis is now defined as systemic inflammatory response syndrome (SIRS) in which there is an identifiable focus of infection. As a consequence of the overactive SIRS response, the function of various organ systems may be compromised, resulting in multiple organ dysfunction syndrome (MODS) and death. Systemic inflammation is a consequence of activation of the innate immune system. It is characterized by intravascular release of pro-inflammatory cytokines and other vasoactive mediators, and the concurrent activation of the innate immune cells. In addition to the pro-inflammatory reactions, the host`s anti-inflammatory mechanisms are also activated and aimed at counteracting the inflammatory response. The balance between pro- and anti-inflammatory reactions is critical for the outcome of the patient. Understanding the mechanisms of acute inflammatory responses in critical ill patients is necessary for the development of urgently needed therapeutics. The aim of this review is to provide a description of the key components and mechanisms involved in the inflammatory response in patients with SIRS and sepsis.
참고문헌 (43)
- Bernard GR, "Efficacy and safety of recombinant human activated protein C for severe sepsis", N Engl J Med, 344, pp.699~709 (2001)
- Annane D, "CUB-Réa Network: Current epidemiology of septic shock: the CUB-Réa Network", Am J Respir Crit Care Med, 168, pp.165~172 (2003)
- Bone RC, "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP", SCCM Consensus Conference Committee. American College of Chest Physicians, Chest, pp.1992, 101[DOI]
- Bone RC, "Sir Isaac Newton, sepsis, SIRS, and CARS", Crit Care Med, 24, pp.1125~1128 (1996)
- Martin GS, "The epidemiology of sepsis in the United States from 1979 through 2000", N Engl J Med, 348, pp.1546~1554 (2003)
- Bone RC, "Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS)", Ann Intern Med, 125, pp.680~687 (1996)
- Kox WJ, "Immunomodulatory therapies in sepsis", Intensive Care Med, 26(Suppl 1), pp.S124~S128 (2000)
- Modlin RL, "The toll of innate immunity on microbial pathogens", N Engl J Med, 340, pp.1834~1835 (1999)
- Brown MA, "NF-kappaB action in sepsis: the innate immune system and the heart", Front Biosci, 9, pp.1201~1217 (2004)
- Reinhart K, "Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned", Crit Care Med, 29(Suppl 7), pp.S121~S125 (2001)
- Panacek EA, "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels", Crit Care Med, 32, pp.2173~2182 (2004)
- Abbas AK, "Functional diversity of helper T lymphocytes", Nature, 383, pp.787~793 (1996)
- Ward NS, "The compensatory anti-inflammatory syndrome (CARS) in critically ill patients", Clin Chest Med, 29, pp.617~625 (2008)
- Oberholzer A, "Sepsis syndromes: understanding the role of innate and acquired immunity", Shock, 16, pp.83~96 (2001)
- Ertel W, "Downregulation of proinflammatory cytokine release in whole blood from septic patients", Blood, 85, pp.1341~1347 (1995)
- Hotchkiss RS, "Apoptosis and caspases regulate death and inflammation in sepsis", Nat Rev Immunol, 6, pp.813~822 (2006)
- Scumpia PO, "Biology of interleukin-10 and its regulatory roles in sepsis syndromes", Crit Care Med, 33(Suppl 12), pp.S468~S471 (2005)
- Abraham E, "Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death", N Engl J Med, 353, pp.1332~1341 (2005)
- Wesche DE, "Leukocyte apoptosis and its significance in sepsis and shock", J Leukoc Biol, 78, pp.325~337 (2005)
- Hotchkiss RS, "Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis", Proc Natl Acad Sci U S A, 100, pp.6724~6729 (2003)
- Bannerman DD, "Mechanisms of bacterial lipopolysaccharide- induced endothelial apoptosis", Am J Physiol Lung Cell Mol Physiol, 284, pp.L899~914 (2003)
- Hotchkiss RS, "Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis", J Immunol, 162, pp.4148~4156 (1999)
- Bommhardt U, "Akt decreases lymphocyte apoptosis and improves survival in sepsis", J Immunol, 172, pp.7583~7591 (2004)
- Hotchkiss RS, "Prevention of lymphocyte cell death in sepsis improves survival in mice", Proc Natl Acad Sci U S A, 96, pp.14541~14546 (1999)
- Hotchkiss RS, "Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte", Nat Immunol, 1, pp.496~501 (2000)
- Wang H, "HMG-1 as a late mediator of endotoxin lethality in mice", Science, 285, pp.248~251 (1999)
- Lotze MT, "High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal", Nat Rev Immunol, 5, pp.331~342 (2005)
- Yu M, "HMGB1 signals through toll-like receptor (TLR) 4 and TLR2", Shock, 26, pp.174~179 (2006)
- Fiuza C, "Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells", Blood, 101, pp.2652~2660 (2003)
- Raman KG, "The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock", Am J Physiol Gastrointest Liver Physiol, 291, pp.G556~565 (2006)
- Andersson J, "The inflammatory reflex--introduction", J Intern Med, 257, pp.122~125 (2005)
- Czura CJ, "Autonomic neural regulation of immunity", J Intern Med, 257, pp.156~166 (2005)
- Banks WA, "Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes", Neuroimmunomodulation, 10, pp.319~327 (2002)
- Maier SF, "The role of the vagus nerve in cytokine-to-brain communication", Ann N Y Acad Sci, 840, pp.289~300 (1998)
- Borovikova LV, "Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin", Nature, 405, pp.458~462 (2000)
- Wang H, "Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation", Nature, 421, pp.384~388 (2003)
- Saeed RW, "Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation", J Exp Med, 201, pp.1113~1123 (2005)
- Borovikova LV, "Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation", Auton Neurosci, 85, pp.141~147 (2000)
- Wang H, "Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis", Nat Med, 10, pp.1216~1221 (2004)
- Dahlbäck B, "Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition", Arterioscler Thromb Vasc Biol, 25, pp.1311~1320 (2005)
- Yuksel M, "Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes", Thromb Haemost, 88, pp.267~273 (2002)
- Zeng W, "Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling", Crit Care Med, 32(Suppl 5), pp.S302~308 (2004)
- Fourrier F, "Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies", Chest, 101, pp.816~823 (1992)